Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001197571 | SCV001368350 | uncertain significance | Stromme syndrome | 2019-04-24 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence favors the benign nature of this variant, however the evidence is insufficent to prove its benign nature. The following ACMG criteria were applied in classifying this variant: PM2,BP1. |
Fulgent Genetics, |
RCV001197571 | SCV002783917 | uncertain significance | Stromme syndrome | 2021-08-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002559260 | SCV003288184 | uncertain significance | not provided | 2022-06-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 2940 of the CENPF protein (p.Glu2940Gln). This variant is present in population databases (rs535739714, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with CENPF-related conditions. ClinVar contains an entry for this variant (Variation ID: 931208). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |